🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 21 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 14/05/2013 | 80,27 | 81,76 | 80,16 | 81,01 | +1,07% | 1,99% | 2.169.900 |
| 13/05/2013 | 79,53 | 81,83 | 79,17 | 80,15 | -0,35% | 3,34% | 3.457.400 |
| 10/05/2013 | 76,61 | 81,04 | 76,53 | 80,43 | +4,75% | 5,89% | 2.724.600 |
| 09/05/2013 | 75,23 | 77,13 | 74,95 | 76,78 | +1,79% | 2,90% | 2.089.200 |
| 08/05/2013 | 76,42 | 76,43 | 74,82 | 75,43 | -1,27% | 2,11% | 1.845.600 |
| 07/05/2013 | 76,92 | 77,39 | 75,98 | 76,40 | -1,10% | 1,83% | 1.738.900 |
| 06/05/2013 | 76,12 | 77,80 | 75,51 | 77,25 | +1,66% | 3,01% | 2.233.300 |
| 03/05/2013 | 75,90 | 79,41 | 74,61 | 75,99 | -2,23% | 6,32% | 3.752.600 |
| 02/05/2013 | 76,30 | 78,04 | 76,16 | 77,72 | +1,16% | 2,46% | 2.159.400 |
| 01/05/2013 | 77,35 | 79,23 | 76,67 | 76,83 | +0,01% | 3,31% | 2.466.200 |
| 30/04/2013 | 77,88 | 78,04 | 75,96 | 76,82 | -1,93% | 2,67% | 3.698.200 |
| 29/04/2013 | 79,00 | 80,41 | 78,25 | 78,33 | -0,87% | 2,73% | 1.892.900 |
| 26/04/2013 | 80,32 | 80,90 | 78,37 | 79,02 | -1,62% | 3,15% | 2.965.100 |
| 25/04/2013 | 80,96 | 81,19 | 79,39 | 80,32 | -0,90% | 2,22% | 2.875.200 |
| 24/04/2013 | 81,27 | 81,56 | 78,78 | 81,05 | -2,97% | 3,42% | 4.471.000 |
| 23/04/2013 | 83,24 | 85,22 | 82,77 | 83,53 | +1,46% | 2,94% | 3.542.700 |
| 22/04/2013 | 84,40 | 87,47 | 80,90 | 82,33 | -3,82% | 7,78% | 8.902.000 |
| 19/04/2013 | 81,55 | 85,90 | 80,10 | 85,60 | +61,91% | 7,11% | 24.895.000 |
| 18/04/2013 | 54,14 | 54,15 | 51,96 | 52,87 | -2,17% | 4,05% | 6.195.700 |
| 17/04/2013 | 54,06 | 54,32 | 52,77 | 54,04 | -0,64% | 2,87% | 1.346.300 |
| 16/04/2013 | 54,59 | 54,74 | 53,25 | 54,39 | +0,61% | 2,73% | 1.450.600 |
| 15/04/2013 | 55,54 | 55,79 | 53,82 | 54,06 | -3,01% | 3,55% | 1.571.800 |
| 12/04/2013 | 54,85 | 55,90 | 54,31 | 55,74 | +1,66% | 2,90% | 1.342.800 |
| 11/04/2013 | 54,72 | 55,73 | 53,64 | 54,83 | -0,02% | 3,82% | 1.040.200 |
| 10/04/2013 | 53,45 | 55,04 | 52,95 | 54,84 | +4,26% | 3,91% | 1.646.700 |
| 09/04/2013 | 52,95 | 53,16 | 51,91 | 52,60 | -0,27% | 2,36% | 1.535.600 |
| 08/04/2013 | 52,65 | 53,13 | 51,28 | 52,74 | -0,92% | 3,51% | 1.710.800 |
| 05/04/2013 | 52,25 | 53,33 | 51,55 | 53,23 | +0,53% | 3,41% | 1.724.000 |
| 04/04/2013 | 53,59 | 53,63 | 52,03 | 52,95 | +0,61% | 2,99% | 1.344.100 |
| 03/04/2013 | 54,45 | 54,55 | 52,43 | 52,63 | -2,41% | 3,89% | 2.142.000 |